Haemonetics Corp (HAE) - NYSE
  • Jul. 26, 2015, 5:30 PM
  • Apr. 27, 2015, 6:52 AM
    • Haemonetics (HAE +1.7%) FQ4 results: Revenues: $226.5M (-6.1%); Gross Profit: $108.4M (-6.1%); R&D Expense: $17.2M (+24.6%); SG&A: $79.6M (-10.8%); Operating Income: $11.5M (-7.3%); Net Loss: ($2.9M) (-128.4%); Loss Per Share: ($0.06) (-131.6%).
    • FY2015 results: Revenues: $910.4M (-3.0%); Gross Profit: $434.4M (-7.3%); R&D Expense: $54.2M (unch); SG&A: $339.7M (-7.6%); Operating Income: $40.5M (-12.7%); Net Income: $16.9M (-51.9%); EPS: $0.32 (-52.2%); Quick Assets: $160.7M (-16.5%).
    • FY2016 Guidance: Revenue growth: 4 - 6%, plasma disposables growth: 12 - 14%, blood center revenue decline: 4 - 6%, hospital disposable growth: 4 - 6%, software solutions growth: 10 - 15%; Adjusted EPS: $1.98 - 2.08; FCF: ~$105M - 110M.
    | Apr. 27, 2015, 6:52 AM
  • Apr. 27, 2015, 6:04 AM
    • Haemonetics (NYSE:HAE): FQ4 EPS of $0.47 misses by $0.05.
    • Revenue of $226.48M (-6.1% Y/Y) misses by $12.74M.
    | Apr. 27, 2015, 6:04 AM
  • Apr. 26, 2015, 5:30 PM
  • Apr. 14, 2015, 1:39 PM
    • Haemonetics (HAE -2.5%) slumps again today on average volume. Shares are down 6% from Friday's close of $44.76.
    • Yesterday, independent equity research firm Off Wall Street Consulting Group issued a Strong Sell recommendation with a $35 price target, citing fewer transfusions due to perceived risks (financial and otherwise) and a growing number of hospitals that are collecting platelets in-house using other manufacturers' equipment.
    • The company is scheduled to report fiscal Q4 and full-year results on April 27 before the open. Consensus views for fiscal Q4 and fiscal 2015 are EPS of $0.52 and $1.90 on revenues of $239M and $923M, respectively.
    | Apr. 14, 2015, 1:39 PM | 1 Comment
  • Jan. 29, 2015, 8:13 AM
    • Haemonetics (NYSE:HAE): FQ3 EPS of $0.53 beats by $0.02.
    • Revenue of $231.83M (-4.2% Y/Y) misses by $3.02M.
    | Jan. 29, 2015, 8:13 AM
  • Jan. 28, 2015, 5:30 PM
  • Jan. 26, 2015, 1:01 PM
    • Because of the severe snow storm, Haemonetics (HAE -0.1%) will now report fiscal Q3 results on January 29 before the open. The conference call will begin at 10:00 am ET.
    • Consensus view is EPS of $0.51 on revenues of $235M.
    | Jan. 26, 2015, 1:01 PM
  • Dec. 29, 2014, 8:50 AM
    • Haemonetics (NYSE:HAE) will report fiscal Q3 results on January 28 before the open. The conference call will begin at 8:00 am ET.
    • Consensus view is EPS of $0.51 on revenues of $235M.
    | Dec. 29, 2014, 8:50 AM
  • Nov. 3, 2014, 7:54 AM
    • Haemonetics (HAE -1.9%) FQ2 results: Revenues: $227.6M (-3.5%); Gross Profit: $108.1M (-9.8%); R&D Expense: $10.9M (-26.8%); SG&A: $84.8M (+4.0%); Operating Income: $12.4M (-47.0%); Net Income: $7.5M (-54.5%); EPS: $0.47 (-28.8%); Quick Assets: $130M (-32.5%); CF Ops: $31.2M (+6.1%).
    • Fiscal 2015 Guidance: Revenue decline: 0 - 2% (unch), plasma disposables growth: 7 - 9% (unch), blood center revenue decline: 10 -12% (unch), hospital disposable growth: 4 - 6% (unch), software solutions growth: 2 - 4% (unch); adjusted gross margin: ~50% (unch); adjusted operating income: $140M - 150M (unch); non-GAAP EPS: $1.85 - 1.95 (unch); FCF: $100M - 110M from $120M - 130M.
    | Nov. 3, 2014, 7:54 AM
  • Nov. 3, 2014, 6:02 AM
    • Haemonetics (NYSE:HAE): FQ2 EPS of $0.47 beats by $0.01.
    • Revenue of $227.58M (-3.5% Y/Y) misses by $2.32M.
    | Nov. 3, 2014, 6:02 AM
  • Nov. 2, 2014, 5:30 PM
  • Nov. 1, 2014, 5:46 PM
    • Haemonetics (NYSE:HAE) will report fiscal Q2 results on November 3 before the open. The conference call will begin at 8:00 am ET.
    • Consensus view is EPS of $0.46 on revenues of $230M.
    | Nov. 1, 2014, 5:46 PM
  • Jul. 30, 2014, 8:25 AM
    • Haemonetics (NYSE:HAE) fiscal Q1 results: Net Revenues: $224.5M (+2.3%); Gross Profit: $106.3M (-4.6%); Operating Expenses: $107.9M (-8.5%); Operating Loss: ($1.7M) (+74.2%); Net Loss: ($3.6M) (+54.4%); Loss Per Share: ($0.07) (+53.3%); CF Ops: $13.7M (+2.2%).
    • Fiscal 2015 Guidance: Revenue decline: 0 - 2%, plasma disposables growth: 7 - 9%, blood center revenue decline: 10 -12%, hospital disposable growth: 4 - 6%, software solutions growth: 2 - 4%; adjusted gross margin: ~50%; adjusted operating income: $140M - 150M; operating margin: ~16%; income taxes: ~26%; non-GAAP EPS: $1.85 - 1.95; FCF: $120M - 130M.
    • Fiscal 2016 Guidance: Revenue growth: mid-single-digit; adjusted operating earnings growth: double-digit; EPS growth: double-digit.
    | Jul. 30, 2014, 8:25 AM
  • Jul. 30, 2014, 6:06 AM
    • Haemonetics (NYSE:HAE): FQ1 EPS of $0.38 beats by $0.03.
    • Revenue of $215.3M (+2.4% Y/Y) misses by $0.55M.
    | Jul. 30, 2014, 6:06 AM
  • Apr. 28, 2014, 11:23 AM
    • Q4
    • Total revenues: $241.1M (-4%).
    • Plasma: $74.1M (+9%).
    • Blood center: platelet disposables: $38.9M (-12%) red cell disposables: $12.3M (-12%) whole blood disposables: $44.8M (-18%).
    • Hospital: surgical disposables: $17.6M (0%), OrthoPAT: $6.1M (-24%), diagnostics disposables: $9.2M (+28%).
    • Software: $19M (+10%).
    • Equipment: $19.2M (+10%).
    • Net income: $10.2M (-19%).
    • EPS: $0.19 (-20.8%)
    • Fiscal year
    • Total revenues: $938.5M (+5%).
    • Net income: $35.1M (-9.5%).
    • EPS: $0.67 (-9%).
    • Fiscal 2015 guidance:
    • Total revenue growth: 0% - 2%.
    • Adjusted gross margin: ~50%.
    • Operating income yield: ~16%.
    • FCF: $120M - $130M.
    • (HAE -9%)
    | Apr. 28, 2014, 11:23 AM
Company Description
Haemonetics Corp. is a global healthcare company, which provides innovative blood management solutions. Its products are divided into four categories: Plasma, Blood Center, Hospital, and Software Solutions. The Plasma product line includes plasma collection for fractionation. The Blood Center... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States